Last reviewed 2026-04-23 · How we verify

bIAP bolus and 8h infusion

Alloksys Life Sciences B.V. · Phase 3 active Small molecule

bIAP bolus and 8h infusion is a Caspase-1 inhibitor Small molecule drug developed by Alloksys Life Sciences B.V.. It is currently in Phase 3 development for Treatment of pyroptosis-related diseases.

bIAP is a caspase-1 inhibitor that blocks the activation of inflammatory caspases.

bIAP is a caspase-1 inhibitor that blocks the activation of inflammatory caspases. Used for Treatment of pyroptosis-related diseases.

At a glance

Generic name	bIAP bolus and 8h infusion
Sponsor	Alloksys Life Sciences B.V.
Drug class	Caspase-1 inhibitor
Target	Caspase-1
Modality	Small molecule
Therapeutic area	Inflammatory diseases
Phase	Phase 3

Mechanism of action

bIAP works by binding to the CARD domain of caspase-1, preventing its activation and subsequent cleavage of pro-inflammatory cytokines. This mechanism is thought to reduce inflammation and tissue damage in various conditions.

Approved indications

Treatment of pyroptosis-related diseases

Common side effects

Nausea
Vomiting
Diarrhea

Key clinical trials

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

bIAP bolus and 8h infusion CI brief — competitive landscape report
bIAP bolus and 8h infusion updates RSS · CI watch RSS
Alloksys Life Sciences B.V. portfolio CI

Frequently asked questions about bIAP bolus and 8h infusion

What is bIAP bolus and 8h infusion?

bIAP bolus and 8h infusion is a Caspase-1 inhibitor drug developed by Alloksys Life Sciences B.V., indicated for Treatment of pyroptosis-related diseases.

How does bIAP bolus and 8h infusion work?

bIAP is a caspase-1 inhibitor that blocks the activation of inflammatory caspases.

What is bIAP bolus and 8h infusion used for?

bIAP bolus and 8h infusion is indicated for Treatment of pyroptosis-related diseases.

Who makes bIAP bolus and 8h infusion?

bIAP bolus and 8h infusion is developed by Alloksys Life Sciences B.V. (see full Alloksys Life Sciences B.V. pipeline at /company/alloksys-life-sciences-b-v).

What drug class is bIAP bolus and 8h infusion in?

bIAP bolus and 8h infusion belongs to the Caspase-1 inhibitor class. See all Caspase-1 inhibitor drugs at /class/caspase-1-inhibitor.

What development phase is bIAP bolus and 8h infusion in?

bIAP bolus and 8h infusion is in Phase 3.

What are the side effects of bIAP bolus and 8h infusion?

Common side effects of bIAP bolus and 8h infusion include Nausea, Vomiting, Diarrhea.

What does bIAP bolus and 8h infusion target?

bIAP bolus and 8h infusion targets Caspase-1 and is a Caspase-1 inhibitor.

Drug class: All Caspase-1 inhibitor drugs
Target: All drugs targeting Caspase-1
Manufacturer: Alloksys Life Sciences B.V. — full pipeline
Therapeutic area: All drugs in Inflammatory diseases
Indication: Drugs for Treatment of pyroptosis-related diseases
Compare: bIAP bolus and 8h infusion vs similar drugs
Pricing: bIAP bolus and 8h infusion cost, discount & access